-transparent.png){kind=logo}
Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals. 1996
A M Been-Tiktak, and
I Williams, and
H M Vrehen, and
J Richens, and
D Aldam, and
A M van Loon, and
C Loveday, and
C A Boucher, and
P Ward, and
I V Weller, and
J C Borleffs
Department of Internal Medicine, University Hospital Utrecht, The Netherlands.
Atevirdine is a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). In this study we investigated the effect of atevirdine in asymptomatic antiretroviral naive HIV-infected patients with CD4+ cell counts of between 200 and 750 cells per mm3. Patients were randomized to receive 600 mg of atevirdine (n = 15) or a placebo (n = 15) three times a day for 12 weeks. There was no statistically significant effect of atevirdine on viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4+ cell counts. The data do not support the use of atevirdine as a monotherapy in the treatment of HIV-infected patients.
Related Publications
A M Been-Tiktak, and
I Williams, and
H M Vrehen, and
J Richens, and
D Aldam, and
A M van Loon, and
C Loveday, and
C A Boucher, and
P Ward, and
I V Weller, and
J C Borleffs
March 1995,
Antimicrobial agents and chemotherapy,
A M Been-Tiktak, and
I Williams, and
H M Vrehen, and
J Richens, and
D Aldam, and
A M van Loon, and
C Loveday, and
C A Boucher, and
P Ward, and
I V Weller, and
J C Borleffs
January 1991,
Journal of acquired immune deficiency syndromes,
A M Been-Tiktak, and
I Williams, and
H M Vrehen, and
J Richens, and
D Aldam, and
A M van Loon, and
C Loveday, and
C A Boucher, and
P Ward, and
I V Weller, and
J C Borleffs
November 1988,
Journal of clinical immunology,
A M Been-Tiktak, and
I Williams, and
H M Vrehen, and
J Richens, and
D Aldam, and
A M van Loon, and
C Loveday, and
C A Boucher, and
P Ward, and
I V Weller, and
J C Borleffs
January 1994,
Psychosomatic medicine,
A M Been-Tiktak, and
I Williams, and
H M Vrehen, and
J Richens, and
D Aldam, and
A M van Loon, and
C Loveday, and
C A Boucher, and
P Ward, and
I V Weller, and
J C Borleffs
October 2010,
The Pediatric infectious disease journal,
A M Been-Tiktak, and
I Williams, and
H M Vrehen, and
J Richens, and
D Aldam, and
A M van Loon, and
C Loveday, and
C A Boucher, and
P Ward, and
I V Weller, and
J C Borleffs
January 2015,
International ophthalmology clinics,
A M Been-Tiktak, and
I Williams, and
H M Vrehen, and
J Richens, and
D Aldam, and
A M van Loon, and
C Loveday, and
C A Boucher, and
P Ward, and
I V Weller, and
J C Borleffs
October 1991,
Clinical pharmacology and therapeutics,
A M Been-Tiktak, and
I Williams, and
H M Vrehen, and
J Richens, and
D Aldam, and
A M van Loon, and
C Loveday, and
C A Boucher, and
P Ward, and
I V Weller, and
J C Borleffs
January 1996,
The Journal of neuropsychiatry and clinical neurosciences,
A M Been-Tiktak, and
I Williams, and
H M Vrehen, and
J Richens, and
D Aldam, and
A M van Loon, and
C Loveday, and
C A Boucher, and
P Ward, and
I V Weller, and
J C Borleffs
January 1998,
Advances in internal medicine,
A M Been-Tiktak, and
I Williams, and
H M Vrehen, and
J Richens, and
D Aldam, and
A M van Loon, and
C Loveday, and
C A Boucher, and
P Ward, and
I V Weller, and
J C Borleffs
March 1996,
Antimicrobial agents and chemotherapy,
